213 related articles for article (PubMed ID: 37799359)
1. Inhibition of vascular endothelial growth factor-A downregulates angiogenesis in psoriasis: A pilot study.
Luengas-Martinez A; Ismail D; Paus R; Young HS
Skin Health Dis; 2023 Oct; 3(5):e245. PubMed ID: 37799359
[TBL] [Abstract][Full Text] [Related]
2. Vascular Endothelial Growth Factor Blockade Induces Dermal Endothelial Cell Apoptosis in a Clinically Relevant Skin Organ Culture Model.
Luengas-Martinez A; Hardman-Smart J; Rutkowski D; Purba TS; Paus R; Young HS
Skin Pharmacol Physiol; 2020; 33(3):110-118. PubMed ID: 32570235
[TBL] [Abstract][Full Text] [Related]
3. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis.
Bhushan M; McLaughlin B; Weiss JB; Griffiths CE
Br J Dermatol; 1999 Dec; 141(6):1054-60. PubMed ID: 10606852
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous vascular structure and perfusion in patients with chronic plaque psoriasis.
Luengas-Martinez A; Kamaly-Asl A; Chaudhry IH; Brenchley PEC; Young HS
Clin Exp Dermatol; 2023 Mar; 48(3):181-187. PubMed ID: 36763714
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of vascular endothelial growth factor (VEGF) receptors on keratinocytes in psoriasis: regulated by calcium independent of VEGF.
Man XY; Yang XH; Cai SQ; Bu ZY; Zheng M
J Cell Mol Med; 2008 Apr; 12(2):649-60. PubMed ID: 18419602
[TBL] [Abstract][Full Text] [Related]
6. Serum neurotensin (NT) is increased in psoriasis and NT induces vascular endothelial growth factor release from human mast cells.
Vasiadi M; Therianou A; Alysandratos KD; Katsarou-Katsari A; Petrakopoulou T; Theoharides A; Papadavid E; Stavrianeas N; Antoniou C; Kalogeromitros D; Theoharides TC
Br J Dermatol; 2012 Jun; 166(6):1349-52. PubMed ID: 22283733
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor-A as a promising therapeutic target for the management of psoriasis.
Luengas-Martinez A; Hardman-Smart J; Paus R; Young HS
Exp Dermatol; 2020 Aug; 29(8):687-698. PubMed ID: 32654325
[TBL] [Abstract][Full Text] [Related]
8. Histological and transcriptional study of angiogenesis and lymphangiogenesis in uninvolved skin, acute pinpoint lesions and established psoriasis plaques: an approach of vascular development chronology in psoriasis.
Henno A; Blacher S; Lambert CA; Deroanne C; Noël A; Lapière C; de la Brassinne M; Nusgens BV; Colige A
J Dermatol Sci; 2010 Mar; 57(3):162-9. PubMed ID: 20071151
[TBL] [Abstract][Full Text] [Related]
9. Assessment of selected angiogenesis markers in the serum of middle-aged male patients with plaque psoriasis.
Socha M; Kicinski P; Feldo M; Zubilewicz T; Pietrzak A
Dermatol Ther; 2021 Jan; 34(1):e14727. PubMed ID: 33381893
[TBL] [Abstract][Full Text] [Related]
10. HGF, HNRPD, and sFLT1 Interfere with the Induction of VEGF in Patients with Severe Psoriasis.
Sobolev V; Muminova M; Zhukova O; Denisova E; Soboleva A; Potekaev N; Korsunskaya I; Mezentsev A
Curr Mol Med; 2024 Jun; ():. PubMed ID: 38918984
[TBL] [Abstract][Full Text] [Related]
11. Expression of Angiogenic Factors in Psoriasis Vulgaris.
Sankar L; Arumugam D; Boj S; Pradeep P
J Clin Diagn Res; 2017 Mar; 11(3):EC23-EC27. PubMed ID: 28511390
[TBL] [Abstract][Full Text] [Related]
12. Expression of lymphatic markers and lymphatic growth factors in psoriasis before and after anti-TNF treatment.
Moustou AE; Alexandrou P; Stratigos AJ; Giannopoulou I; Vergou T; Katsambas A; Antoniou C
An Bras Dermatol; 2014; 89(6):891-7. PubMed ID: 25387493
[TBL] [Abstract][Full Text] [Related]
13. Expression of Vascular Endothelial Growth Factor and Microvessel Density in Psoriatic Skin Lesions.
Rajan PT; Suresh TN; Rajashekar TS
Indian Dermatol Online J; 2018; 9(6):418-421. PubMed ID: 30505782
[TBL] [Abstract][Full Text] [Related]
14. Altered expression of angiogenesis and lymphangiogenesis markers in the uninvolved skin of plaque-type psoriasis.
Henno A; Blacher S; Lambert C; Colige A; Seidel L; Noël A; Lapière C; de la Brassinne M; Nusgens BV
Br J Dermatol; 2009 Mar; 160(3):581-90. PubMed ID: 18945297
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis--a possible target for novel therapies?
Canavese M; Altruda F; Ruzicka T; Schauber J
J Dermatol Sci; 2010 Jun; 58(3):171-6. PubMed ID: 20430590
[TBL] [Abstract][Full Text] [Related]
16. Antivascular endothelial growth factor-A therapy: a novel personalized treatment approach for psoriasis.
Luengas-Martinez A; Paus R; Young HS
Br J Dermatol; 2022 May; 186(5):782-791. PubMed ID: 34878645
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide Improves Psoriasis-like Lesions and Inhibits Cutaneous VEGF Expression without Alteration of Microvessel Density in Imiquimod- induced Psoriatic Mouse Model.
Liu JH; Wu HH; Zhao YK; Wang F; Gao Q; Luo DQ
Curr Vasc Pharmacol; 2018; 16(5):510-521. PubMed ID: 28982338
[TBL] [Abstract][Full Text] [Related]
18. Novel investigational vascular endothelial growth factor (VEGF) receptor antagonists for psoriasis.
Malecic N; Young HS
Expert Opin Investig Drugs; 2016; 25(4):455-62. PubMed ID: 26864055
[TBL] [Abstract][Full Text] [Related]
19. Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor.
Creamer D; Allen M; Jaggar R; Stevens R; Bicknell R; Barker J
Arch Dermatol; 2002 Jun; 138(6):791-6. PubMed ID: 12056961
[TBL] [Abstract][Full Text] [Related]
20. Significance of vascular endothelial growth factor and CD31 and morphometric analysis of microvessel density by CD31 receptor expression as an adjuvant tool in diagnosis of psoriatic lesions of skin.
Chawla N; Kataria SP; Aggarwal K; Chauhan P; Kumar D
Indian J Pathol Microbiol; 2017; 60(2):189-195. PubMed ID: 28631633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
